Recombinant Factor VIIa (Eptacog Alfa)
Authors:
- 1 January 2005
- journal article
- review article
- Published by Springer Nature in Drugs
- Vol. 65 (8) , 1161-1177
Abstract
Recombinant factor VIIa (NovoSeven®) [also known as recombinant activated factor VII or eptacog alfa] is a vitamin K-dependent glycoprotein that is structurally similar to human plasma-derived factor VIIa. It is a recombinant product, manufactured using DNA biotechnology. Intravenous recombinant factor VIIa has been evaluated in the treatment of bleeding episodes and for providing haemostasis cover during surgery in patients with certain bleeding disorders. Large, well controlled trials of recombinant factor VIIa have not been performed because of the rarity of these bleeding disorders. However, the efficacy of recombinant factor VIIa has been investigated in these patients in double-blind dose-finding or noncomparative clinical trials and worldwide compassionate-use programmes. Recombinant factor VIIa is effective and generally well tolerated in patients with haemophilia A or B with inhibitors, those with acquired haemophilia or Glanzmann’s thrombasthenia. Also, recombinant factor VIIa is a treatment of choice in patients with haemophilia B with high-responding inhibitors and those with factor VII deficiency. Direct head-to-head comparisons and robust pharmacoeconomic data are required to fully determine the position of recombinant factor VIIa in relation to other therapies. Importantly though, the product appears to be relatively free of antigenicity, thrombogenicity and risk of viral transmission that, in the past, have limited the utility of blood products. Given that these characteristics are important determinants of the place of a treatment in bleeding disorders, recombinant factor VIIa provides a valuable treatment alternative in patients with haemophilia with inhibitors, platelet-refractory Glanzmann’s thrombasthenia or congenital factor VII deficiency. In patients with haemophilia, exogenous administration of high (supraphysiological) concentrations of recombinant factor VIIa bypasses the factor VIII/IX pathway via tissue factor-dependent or -independent mechanisms. Similar mechanisms are likely to be operative in patients with Glanzmann’s thrombasthenia. In clinical studies, decreases in prothrombin time and activated partial thromboplastin time in patients with haemophilia were not accompanied by any laboratory test results indicative of systemic activation of coagulation. Isolated reports have documented the development of specific antibodies to recombinant factor VIIa. Intravenous recombinant factor VIIa generally has linear pharmacokinetics; clearance (CL), steady-state volume of distribution (Vdss), terminal half-life (t1/2) and mean residence time are all dose-independent in adult patients with haemophilia A. It has a short t1/2 (2–3 hours). Compared with the values in adult haemophilia patients, CL values of recombinant factor VIIa were higher in paediatric haemophilia patients and adult patients with severe congenital factor VII deficiency; the latter group also had higher Vdss and lower recovery (ratio of measured: expected peak plasma factor VII clotting activity) values. Intravenous recombinant factor VIIa has been most commonly used at a dosage of approximately 90 μg/kg every 2–4 hours in patients with haemophilia with inhibitors or Glanzmann’s thrombasthenia; a lower dose of 15–30 μg/kg was generally used in patients with congenital factor VII deficiency. In randomised, double-blind dose-finding trials in patients with haemophilia (mostly those with inhibitors), recombinant factor VIIa showed good haemostatic efficacy at doses of 35–90 μg/kg. In one trial, recombinant factor VIIa 90 μg/kg provided satisfactory haemostasis cover against intraoperative bleeding in 93% (13 of 14) of patients. Recombinant factor VIIa has been successfully used in patients with congenital haemophilia with inhibitors who had a life- or limb-threatening bleeding episode, or were refractory to alternative treatments in the worldwide compassionate- or emergency-use programmes. In these programmes, excellent or effective haemostasis was achieved in 62–88% of serious bleeding episodes, mainly in patients with congenital haemophilia A or B with inhibitors. The efficacy rates were even higher (up to 93%) in the noncomparative, home-treatment trials in patients with bleeding episodes and with a short time lag before the commencement of treatment, suggesting better efficacy with early treatment. Several other reports from the compassionate-use programme have documented efficacy rates of 81–100% with recombinant factor VIIa in controlling bleeding during major or minor surgical procedures. Similar efficacy rates have been reported in a limited number of patients with acquired haemophilia, including those with serious bleeding episodes, treated with recombinant factor VIIa during the compassionate-use programme or in an Italian registry programme. According to data from a Canadian pilot study and an international registry, recombinant factor VIIa was effective in producing haemostasis in up to 97% of nonsurgical bleeding episodes and in 94% of surgical procedures in patients with Glanzmann’s thrombasthenia. Data from a limited number of patients with congenital factor VII deficiency have shown that recombinant factor VIIa provides effective haemostasis in nonsurgical bleeding or during surgical procedures in these patients. With over a decade of use, recombinant factor VIIa has generally been well tolerated during administration of more than 700 000 injections in patients with haemophilia with inhibitors or other bleeding disorders. Serious adverse events (incidence approximately ≤1%) with recombinant factor VIIa include thrombotic events (myocardial infarction, cerebrovascular events, thromboembolism and disseminated intravascular coagulation), angina, tachycardia, ataxia, acute renal failure, anaphylactic shock and abnormal liver function, with a majority of the thrombotic events occurring in patients with predisposing factors. Home-treatment trials have reported no serious adverse events (possibly or probably treatment-related or of unknown relationship). Adverse events have not been linked to the dose or frequency of administration of recombinant factor VIIa.Keywords
This publication has 81 references indexed in Scilit:
- Comparative thrombotic event incidence after infusion of recombinant factor VIIa vs. factor VIII inhibitor bypass activity—a rebuttalJournal of Thrombosis and Haemostasis, 2005
- Inhibitor to factor VII in severe factor VII deficiency: detection and course of the inhibitory responseJournal of Thrombosis and Haemostasis, 2005
- Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society RegistryHaemophilia, 2005
- The use of recombinant factor VIIa in the treatment of bleeding disordersBlood, 2004
- Elective orthopedic surgery for hemophilia patients with inhibitors: new opportunitiesSeminars in Hematology, 2004
- Treatment of the Bleeding Inhibitor PatientSeminars in Thrombosis and Hemostasis, 2003
- Recombinant factor VIIa (NovoSeven[reg ]) as a hemostatic agentDisease-a-Month, 2003
- Does recombinant factor VIIa, apart from overall hemostasis, regulate TAFI dependent fibrinolysis? In vitro analysis using overall hemostasis potential (OHP) assayThrombosis and Haemostasis, 2003
- Determinants of Drug Costs in Hospitalised Patients with HaemophiliaPharmacoEconomics, 2003
- Recombinant Factor VIla (NovoSeven®) in the Treatment of Internal Bleeding in Patients with Factor VIM and IX InhibitorsPathophysiology of Haemostasis and Thrombosis, 1996